Dr Lalchand. Lab

Which are the latest news on Dr Lalchand. Lab?

Why is Dr Lalchandani Labs Ltd falling/rising?

As of 05-Sep, Dr Lalchandani Labs Ltd's stock price is declining, currently at 7.64, reflecting a -4.98% change. This decline is due to underperformance against the Sensex and sector, mixed moving average signals, and a significant drop in investor participation.

As of 05-Sep, Dr Lalchandani Labs Ltd's stock price is falling, currently at 7.64, which reflects a change of -0.4, or -4.98%. This decline can be attributed to several factors. Over the past week, the stock has underperformed the benchmark Sensex, with a decrease of -0.39% compared to the Sensex's -0.97%. Although the stock has shown a positive return of +4.51% over the past month, it has significantly underperformed year-to-date, with a decline of -50.33% against the Sensex's -10.21%. <BR><BR>Additionally, today's performance indicates that the stock has underperformed its sector by -3.72%. The moving averages suggest mixed signals; while the stock is higher than the 20-day and 50-day moving averages, it is lower than the 5-day, 100-day, and 200-day moving averages, indicating potential weakness in the short to medium term. Furthermore, there has been a notable decrease in investor participation, with delivery volume dropping by -66.67% compared to the 5-day average. This decline in trading activity could further contribute to the downward pressure on the stock price. Overall, these factors collectively explain the current falling trend of Dr Lalchandani Labs Ltd's stock.

Who are in the management team of Dr Lalchand. Lab?

The management team of Dr Lalchand Lab includes Arjan Lalchandani (Chairman & Managing Director), Mohit Lalchandani (Whole Time Director & CEO), Anchal Gupta (Executive Director & CFO), and independent directors Rajiv Handa and Prakash Jhuraney, along with director Swati Chandra.

The management team of Dr Lalchand Lab includes the following key members:<BR><BR>1. **Arjan Lalchandani** - Chairman & Managing Director<BR>2. **Mohit Lalchandani** - Whole Time Director & CEO<BR>3. **Anchal Gupta** - Executive Director & CFO<BR>4. **Rajiv Handa** - Independent Director<BR>5. **Prakash Jhuraney** - Independent Director<BR>6. **Swati Chandra** - Director<BR><BR>If you need more information about their roles or contributions, feel free to ask!

What does Dr Lalchand. Lab do?

Dr Lalchandani Labs Ltd provides pathology laboratory services and operates as a micro-cap company with a market cap of INR 7 Cr. It was incorporated in 2011 and transitioned to a limited company in 2017.

Overview: <BR>Dr Lalchandani Labs Ltd operates in the healthcare services industry, specifically providing pathology laboratory services, and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was originally incorporated as a partnership firm in New Delhi on 15 September 2011 under the name Dr. A Lalchandani Pathology Laboratories. It transitioned to a limited company on 2 August 2017, following an agreement dated 31 August 2017. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 112.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.15 <BR>Return on Equity: 0.42% <BR>Price to Book: 0.47<BR><BR>Contact Details: <BR>Address: M-20 Basement, Greater Kailash-1 New Delhi New Delhi : 110048 <BR>Tel: 91-11-49057058 <BR>Email: info@lalchandanipathlab.com <BR>Website: http://www.lalchandanipathlab.com

Who are the peers of the Dr Lalchand. Lab?

Peers of Dr Lalchand. Lab include Samsrita Labs, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Family Care, Looks Health, Clinitech Lab, Ashram Online, and Gian Lifecare. Dr Lalchand. Lab has a 1-year return of -58.72%, better than Gian Lifecare's -67.47% but worse than Dhanvantri Jeev.'s 26.19%.

Peers: The peers of Dr Lalchand. Lab are Samsrita Labs, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Family Care, Looks Health, Clinitech Lab, Ashram Online, and Gian Lifecare.<BR><BR>Quality Snapshot: Excellent capital structure is observed at Dhanvantri Jeev., Family Care, Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, while Good capital structure is found at the same companies. Below Average management risk is noted at Vanta Bioscience, Dhanvantri Jeev., Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, while Average management risk is found at Family Care. The rest of the peers do not qualify for management risk, growth, or capital structure.<BR><BR>Return Snapshot: Dhanvantri Jeev. has the highest 1-year return at 26.19%, while Gian Lifecare has the lowest at -67.47%. Dr Lalchand. Lab's 1-year return is -58.72%, which is better than Gian Lifecare but worse than Dhanvantri Jeev. Additionally, Vanta Bioscience, Family Care, Clinitech Lab, Gian Lifecare, and Dr Lalchand. Lab all have negative six-month returns.

How big is Dr Lalchand. Lab?

As of 31st August, Dr Lalchandani Labs Ltd has a market capitalization of 7.00 Cr, classifying it as a Micro Cap company. The latest financial metrics include Shareholder's Funds of 9.96 Cr and Total Assets of 15.75 Cr as of March 2025, with no recent quarterly performance data available.

As of 31st August, Dr Lalchandani Labs Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is not available, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds reported at 9.96 Cr and Total Assets at 15.75 Cr.

Is Dr Lalchand. Lab overvalued or undervalued?

As of December 4, 2025, Dr Lalchand Lab's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 19.83, an EV to EBITDA of 8.75, and a Price to Book Value of 0.84, making it more affordable compared to peers like Max Healthcare and Apollo Hospitals, while also outperforming the Sensex with a year-to-date return of 13.73%.

As of 4 December 2025, the valuation grade for Dr Lalchand. Lab has moved from risky to attractive, indicating a significant improvement in its investment appeal. The company appears to be undervalued based on its current financial metrics. Notable ratios include a PE ratio of 19.83, an EV to EBITDA of 8.75, and a Price to Book Value of 0.84, which suggest that the stock is trading at a discount relative to its earnings and assets.<BR><BR>When compared to peers, Dr Lalchand. Lab's valuation stands out positively. For instance, Max Healthcare is classified as very expensive with a PE ratio of 74.46, while Apollo Hospitals, also attractive, has a PE of 61.81. This comparison highlights Dr Lalchand. Lab's relative affordability in the healthcare services sector. Additionally, the company's recent stock performance shows a year-to-date return of 13.73%, outperforming the Sensex's 9.12%, reinforcing the notion that it may be undervalued in the current market.

How has been the historical performance of Dr Lalchand. Lab?

Dr Lalchand. Lab has experienced a decline in net sales and profitability, with total operating income dropping from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25, and profit before tax decreasing from 1.25 Cr to 0.40 Cr in the same period. Total assets and liabilities also decreased, while cash flow from operating activities remained stagnant, though a net cash inflow of 1.00 Cr was recorded in Mar'25.

Answer:<BR>The historical performance of Dr Lalchand. Lab shows a declining trend in net sales and profitability over the past few years, with a significant drop in total operating income from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. The operating profit margin has fluctuated, peaking at 28.9% in Mar'24 before falling to 23.37% in Mar'25. Profit before tax also saw a decline, moving from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax decreased from 0.93 Cr in Mar'22 to 0.42 Cr in Mar'25. The company’s total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, and total liabilities also saw a reduction from 18.12 Cr to 15.75 Cr in the same period. Cash flow from operating activities has been stagnant, with no inflow reported in the last two years, although there was a net cash inflow of 1.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Lalchand. Lab's financial performance has shown a notable decline in net sales, which decreased from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. This decline is reflected in the total operating income, which also fell significantly over the years. The operating profit margin peaked at 28.9% in Mar'24 but dropped to 23.37% in Mar'25, indicating challenges in maintaining profitability. Profit before tax decreased from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax followed a similar trend, moving from 0.93 Cr to 0.42 Cr. The company's total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, with total liabilities also reducing in the same timeframe. Cash flow from operating activities has remained stagnant, with no inflow in recent years, although a net cash inflow of 1.00 Cr was recorded in Mar'25, suggesting some improvement in liquidity.

When is the next results date for Dr Lalchand. Lab?

Dr Lalchand. Lab will announce its results on 14 November 2025.

Dr Lalchand. Lab is scheduled to declare its results on 14 November 2025.

What is the technical trend for Dr Lalchand. Lab?

As of June 2, 2025, Dr. Lalchand Lab's trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, with weekly indicators showing mild bullishness and monthly indicators remaining bearish.

As of 2 June 2025, the technical trend for Dr Lalchand. Lab has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The daily moving averages are mildly bearish, while the weekly Bollinger Bands are bullish, contrasting with the monthly Bollinger Bands that are mildly bearish. The KST shows a mildly bullish stance on the weekly chart but is bearish on the monthly. Dow Theory indicates no trend on the weekly and mildly bullish on the monthly. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from MACD and Bollinger Bands.

Who are the top shareholders of the Dr Lalchand. Lab?

The top shareholder of Dr Lalchand Lab is Arjan Lal Chandani, with a 42.53% stake, followed by public shareholder Amit Charan at 5.08%. Individual investors own 45.68% of the company, with no institutional or pledged promoter holdings.

The top shareholders of Dr Lalchand Lab include Arjan Lal Chandani, who holds the largest stake at 42.53%. Following him, the highest public shareholder is Amit Charan, with a holding of 5.08%. Additionally, individual investors collectively own 45.68% of the company. Notably, there are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

Has Dr Lalchand. Lab declared dividend?

No Dividend History Available